We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Albemarle (ALB) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
Albemarle (ALB - Free Report) ended the recent trading session at $105.78, demonstrating a -1.71% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.25%. Elsewhere, the Dow saw a downswing of 0.86%, while the tech-heavy Nasdaq appreciated by 0.24%.
The specialty chemicals company's shares have seen a decrease of 20.6% over the last month, not keeping up with the Basic Materials sector's loss of 8.47% and the S&P 500's loss of 0.42%.
Market participants will be closely following the financial results of Albemarle in its upcoming release. The company is forecasted to report an EPS of $2.55, showcasing a 1442.11% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.52 billion, up 16.07% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $11.39 per share and revenue of $6.1 billion, indicating changes of +1541.77% and +18.69%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Albemarle. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. At present, Albemarle boasts a Zacks Rank of #4 (Sell).
Digging into valuation, Albemarle currently has a Forward P/E ratio of 9.45. This signifies a discount in comparison to the average Forward P/E of 15.9 for its industry.
It is also worth noting that ALB currently has a PEG ratio of 0.63. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Chemical - Diversified industry was having an average PEG ratio of 1.18.
The Chemical - Diversified industry is part of the Basic Materials sector. This group has a Zacks Industry Rank of 107, putting it in the top 44% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Albemarle (ALB) Registers a Bigger Fall Than the Market: Important Facts to Note
Albemarle (ALB - Free Report) ended the recent trading session at $105.78, demonstrating a -1.71% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.25%. Elsewhere, the Dow saw a downswing of 0.86%, while the tech-heavy Nasdaq appreciated by 0.24%.
The specialty chemicals company's shares have seen a decrease of 20.6% over the last month, not keeping up with the Basic Materials sector's loss of 8.47% and the S&P 500's loss of 0.42%.
Market participants will be closely following the financial results of Albemarle in its upcoming release. The company is forecasted to report an EPS of $2.55, showcasing a 1442.11% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.52 billion, up 16.07% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $11.39 per share and revenue of $6.1 billion, indicating changes of +1541.77% and +18.69%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Albemarle. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. At present, Albemarle boasts a Zacks Rank of #4 (Sell).
Digging into valuation, Albemarle currently has a Forward P/E ratio of 9.45. This signifies a discount in comparison to the average Forward P/E of 15.9 for its industry.
It is also worth noting that ALB currently has a PEG ratio of 0.63. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Chemical - Diversified industry was having an average PEG ratio of 1.18.
The Chemical - Diversified industry is part of the Basic Materials sector. This group has a Zacks Industry Rank of 107, putting it in the top 44% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.